Twist Bioscience Corp

TWST remains in a Stage 2 uptrend above rising SMAs, but is undergoing a descending retracement into declining short-term EMAs. The medium-term bias is bullish, supported by the mean-reversion pattern suggesting support near the 50-day SMA. However, short-term price action shows a pullback without clear bounce signals, so execution is deferred until a clearer recovery emerges.

• ↑Q3 revenue $118.4M (+23% YoY) with 14th consecutive growth quarter; FY26 guide raised to $456M.
• ↑NGS segment revenue $61.8M (+12% YoY) from 657 clients, signaling market share gains.
• ↓Earnings yield is negative, indicating weak return generation and potential overvaluation.